Psoriasis in Hispanic and Latino Patients Linked to Rising Metabolic Risks

Psoriasis has long been understood as more than a skin disease. The red, scaly plaques that define psoriasis vulgaris are the visible surface of a chronic inflammatory process that travels through the entire body, quietly increasing the risk of cardiovascular disease, diabetes, and other metabolic disorders. A new retrospective cohort analysis published in the Archives of Dermatological Research now turns the spotlight on a population that has often been underrepresented in dermatology research: Hispanic and Latino patients with psoriasis vulgaris, and the metabolic comorbidities that emerge in them over time.

The study, led by Henry Omar Herrera of Case Western Reserve University together with colleagues at University Hospitals Cleveland Medical Center and Albert Einstein College of Medicine, set out to answer a deceptively simple question. When Hispanic or Latino patients are diagnosed with psoriasis, what is their subsequent risk of developing new-onset metabolic conditions such as type 2 diabetes, hypertension, dyslipidemia, obesity-related disorders, and metabolic syndrome? The question matters because psoriasis is already recognized as an independent risk factor for metabolic disease in the general population, but the vast majority of the evidence base has been built on cohorts of European descent.

The biological rationale for the psoriasis-metabolism connection is well established. Psoriasis is driven by a sustained activation of the immune system, particularly T cells and inflammatory signaling molecules such as tumor necrosis factor alpha, interleukin-17, and interleukin-23. These cytokines do not confine their effects to the skin. They circulate systemically, promoting insulin resistance in muscle and liver tissue, altering lipid metabolism, and encouraging the low-grade vascular inflammation that underlies atherosclerosis. Over months and years, this chronic inflammatory state can tip patients toward the metabolic syndrome cluster of abdominal obesity, elevated triglycerides, low HDL cholesterol, high blood pressure, and impaired fasting glucose.

Hispanic and Latino populations in the United States carry a distinct baseline metabolic profile that makes this interaction especially consequential. National surveillance data cited by the authors show that Hispanic Americans experience higher rates of diabetes and several of its complications compared with non-Hispanic white Americans. Large epidemiological surveys, including the landmark JAMA analysis of diabetes prevalence by race and ethnicity from 2011 to 2016, have documented that the burden of diagnosed and undiagnosed diabetes is disproportionately heavy in this community. Layering the systemic inflammation of psoriasis on top of that elevated baseline risk creates a scenario in which even a modest additional inflammatory push could translate into a meaningful increase in new metabolic diagnoses.

Yet, as the authors and prior reviewers have noted, Hispanic and Latino patients with psoriatic disease have historically been a blind spot in the literature. A comprehensive review of psoriatic disease in the US Latino population published in the American Journal of Clinical Dermatology highlighted how little controlled data exist on disease presentation, treatment response, and comorbidity trajectories in this group. Dermatology registries and biologic trials tend to enroll predominantly white participants, which means that risk estimates derived from those datasets may simply not apply to other populations. Genetic ancestry, patterns of adipose tissue distribution, dietary and occupational factors, access to care, and differences in how aggressively comorbidities are screened for can all shift the relationship between skin inflammation and metabolic outcomes.

The retrospective cohort design of the new analysis reflects both the practicality and the limitations of studying these questions with real-world medical records. Rather than randomizing patients to interventions, the researchers looked backward through clinical data, identifying Hispanic or Latino patients with a diagnosis of psoriasis vulgaris and tracking whether they went on to receive new diagnoses of metabolic comorbidities during follow-up. Retrospective cohorts of this kind are powerful for generating incidence estimates and hypothesis-generating risk signals in populations that are rarely captured in prospective trials, but they depend on the completeness and accuracy of the underlying records, and they can be vulnerable to confounding by factors such as body mass index, medication use, and healthcare utilization patterns.

Why does this matter clinically? Dermatologists are increasingly viewed as the first line of defense against the systemic consequences of psoriasis. A patient who presents with plaques on the elbows and scalp is not just a cosmetic or comfort concern; that patient carries a quantifiably elevated lifetime risk of myocardial infarction, stroke, and diabetes. Guidelines from several dermatology societies now recommend that patients with moderate to severe psoriasis undergo periodic screening for metabolic syndrome components, including blood pressure, fasting glucose or hemoglobin A1c, and lipid panels. If Hispanic and Latino patients face a higher trajectory of new-onset metabolic disease after a psoriasis diagnosis, then screening intensity, lifestyle counseling, and early referral to primary care or endocrinology may need to be calibrated differently for this population.

The study also arrives at a moment when the demographics of psoriasis in the United States are shifting. Hispanic Americans represent a large and rapidly growing share of the national population, and psoriasis affects an estimated three percent of US adults overall. Simple arithmetic dictates that the absolute number of Hispanic and Latino individuals living with psoriatic disease will continue to climb. If the comorbidity burden in this group is systematically underestimated, health systems will be caught unprepared for a wave of cardiovascular and diabetic complications that could have been anticipated and, in part, prevented. Health disparities research of this type is therefore not merely academic; it is a matter of resource allocation, screening policy, and ultimately lives saved.

There are also important mechanistic questions raised by population-specific risk research. Adiposity patterns differ across ancestral groups, with some populations showing greater visceral fat deposition at the same body mass index, and visceral fat is a particularly potent source of the inflammatory adipokines that synergize with psoriasis-related cytokines. Genetic variants influencing both immune signaling and lipid metabolism vary in frequency across populations. Socioeconomic factors, including food environments, occupational stress, and barriers to consistent healthcare, further modulate the observed risk. Disentangling these strands requires exactly the kind of targeted cohort work that the Cleveland and Bronx-based team has begun, and it argues for larger, multi-center, prospective studies with granular data on ancestry, disease severity measured by body surface area or PASI scores, and longitudinal metabolic laboratory values.

For now, the practical message for clinicians and patients is clear. Psoriasis in Hispanic and Latino patients should prompt the same vigilance toward metabolic health that the field has learned to apply in other populations, and quite possibly more. Patients should be aware that their skin condition is connected to their heart and metabolic health, and that controlling systemic inflammation, maintaining a healthy weight, staying physically active, and keeping up with metabolic screening are all part of managing psoriasis in the twenty-first century. As the evidence base grows more inclusive, the hope is that risk prediction and preventive care will finally serve every population equally, rather than only those who have historically filled the clinical trials.

Subject of Research: Risk of new-onset metabolic comorbidities in Hispanic or Latino patients with psoriasis vulgaris

Article Title: Risk of new-onset metabolic comorbidities in hispanic or latino patients with psoriasis vulgaris: a retrospective cohort analysis

Article References: Herrera, H. O., Nolasco, B., Sánchez-Feliciano, A., & Bordeaux, J. (2026). Risk of new-onset metabolic comorbidities in hispanic or latino patients with psoriasis vulgaris: a retrospective cohort analysis. Archives of Dermatological Research, 318(1), Article 512. https://doi.org/10.1007/s00403-026-04971-3

Image Credits: AI Generated

DOI: 10.1007/s00403-026-04971-3

Keywords: psoriasis, psoriasis vulgaris, Hispanic health, Latino health, metabolic syndrome, type 2 diabetes, cardiovascular risk, dermatology, health disparities, retrospective cohort, chronic inflammation, comorbidities